Pfizer Inc. (PFE) Release: Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study of Nocturnal Urinary Urgency
11/8/2011 7:08:21 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight during sleep hours after 12 weeks of treatment. Further analyses will be conducted on the initial data, including submission for publication of comprehensive results at a later date.